Centiva Capital’s Gossamer Bio GOSS Stock Holding History

Centiva Capital’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-265,920	Closed	-$335K	–	1768
2023 Q1	$335K	Buy	+265,920	New	+$509K	0.01%	1004

Other funds holding GOSS

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Centiva Capital's GOSS Position: Q2 2023 in Review

Centiva Capital sold out of Gossamer Bio (GOSS) in Q2 2023, closing a stake of 265,920 shares — an estimated $335K sold.

Centiva Capital first reported a position in GOSS in Q1 2023 and held it in 1 quarter. The position peaked at $335K in Q1 2023. 99 funds tracked by Wall St. Rank hold GOSS as of Q2 2023.

Centiva Capital reported no remaining Gossamer Bio position as of Q2 2023 after selling out during the quarter.
Centiva Capital sold 265,920 Gossamer Bio shares in Q2 2023, an estimated $335K.
Centiva Capital first reported a position in Gossamer Bio in Q1 2023 and held it in 1 quarter.
Centiva Capital's Gossamer Bio position peaked at $335K in Q1 2023.
99 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2023.

Based on Centiva Capital's 13F filing for Q2 2023, filed 14 Aug 2023.